PMID- 25421898
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20181202
IS  - 1744-7593 (Electronic)
IS  - 1742-5247 (Linking)
VI  - 12
IP  - 2
DP  - 2015 Feb
TI  - Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug 
      delivery.
PG  - 319-37
LID - 10.1517/17425247.2014.953051 [doi]
AB  - INTRODUCTION: Mesoporous silica nanoparticles (MSNPs) are one of the most 
      promising inorganic drug delivery systems (DDSs). The design and development of 
      tumour-targeted MSNPs with stimuli-responsive drug release capability aim at 
      enhancing the efficiency and minimising the side effects of anti-tumour drugs for 
      cancer therapy. AREAS COVERED: This review provides an overview of the scientific 
      advances in MSNPs for tumour-targeted stimuli-responsive drug delivery. The key 
      factors that govern the passive accumulation of MSNPs within solid tumours such 
      as size, shape and surface functionalisation are roughly described. The different 
      active targeting strategies for the specific retention and uptake of MSNPs by 
      tumour cells are also outlined. The approaches developed so far for the synthesis 
      of smart MSNPs capable of releasing the trapped drugs in response to internal or 
      external stimuli and their applications are reviewed. Critical considerations in 
      the use of MSNPs for the treatment of cancer treatment are discussed. The future 
      prospects and key factors concerning the clinical application of MSNPs are 
      considered throughout the manuscript. EXPERT OPINION: MSNPs are promising 
      nanocarriers to efficiently transport and site-specifically deliver highly toxic 
      drugs, such as chemotherapeutic agents for cancer treatment. However, there are 
      certain issues that should be overcome to improve the suitability of MSNPs for 
      clinical applications. Increasing the penetration capability of MSNPs within 
      tumour tissues, providing them of appropriate colloidal stability in 
      physiological fluids and ensuring that their active targeting capability and 
      stimuli-responsive performance are preserved in complex biological media are of 
      foremost significance. Few in vivo evaluation tests of MSNPs have been reported 
      and much research effort into this field is mandatory to be able to move from 
      bench to bedside.
FAU - Baeza, Alejandro
AU  - Baeza A
AD  - Departamento Quimica Inorganica y Bioinorganica, Facultad de Farmacia, 
      Universidad Complutense de Madrid, Instituto de Investigacion Sanitaria Hospital 
      , 12 de Octubre i+12. Pza. Ramon y Cajal s/n, 28040 Madrid , Spain vallet@ucm.es.
FAU - Colilla, Montserrat
AU  - Colilla M
FAU - Vallet-Regi, Maria
AU  - Vallet-Regi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141125
PL  - England
TA  - Expert Opin Drug Deliv
JT  - Expert opinion on drug delivery
JID - 101228421
RN  - 0 (Antineoplastic Agents)
RN  - 7631-86-9 (Silicon Dioxide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/adverse effects/therapeutic use
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Nanoparticles
MH  - Neoplasms/drug therapy
MH  - Porosity
MH  - Silicon Dioxide/*chemistry
OTO - NOTNLM
OT  - active targeting
OT  - cancer
OT  - mesoporous silica nanoparticles
OT  - passive targeting
OT  - stimuli-responsive drug delivery
EDAT- 2014/11/26 06:00
MHDA- 2015/09/29 06:00
CRDT- 2014/11/26 06:00
PHST- 2014/11/26 06:00 [entrez]
PHST- 2014/11/26 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - 10.1517/17425247.2014.953051 [doi]
PST - ppublish
SO  - Expert Opin Drug Deliv. 2015 Feb;12(2):319-37. doi: 10.1517/17425247.2014.953051. 
      Epub 2014 Nov 25.